Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Critical Limb Ischemia
Interventions: Low Dose VM202, High Dose VM202, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more

Conditions: Function of Renal Transplant
Interventions: Aminophylline, Theophylline drug levels, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Pancreatitis (AP)
Interventions: Lactated Ringer's, Lactated Ringers Stroke Volume Based Dosing; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: Diabetic Ketoacidosis
Interventions: Normal saline, Lactated Ringers; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: Up to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions: Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy; Combination Product
Lead sponsor: Azienda Ospedaliera di Padova; Other
Eligibility: 18 Years and older
Enrollment: 1,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more

Conditions: Pleural Effusion
Interventions: normal saline, TNK (Tenecteplase); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Cardiac Conduction and Repolarization
Interventions: Custirsen, Placebo, Moxifloxacin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Retinopathy of Prematurity (ROP)
Interventions: myo-Inositol 5% Injection, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Large Polyps in the Gastrointestinal Tract
Interventions: Autologous blood injection, Normal saline, HPMC; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Salt Sensitivity of Blood Pressure
Interventions: Hypertonic Saline with furosemide, Hypertonic Saline without furosemide; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Transplantation, Kidney
Interventions: Transversus abdominis plane (TAP) block, Sham TAP block with normal saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autism Spectrum Disorders
Interventions: Suramin, Saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Years to 17 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Post-operative Pain, Respiratory Depression
Interventions: Dexmedetomidine, Placebo (Normal Saline); Drug · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Post Surgical Pain
Interventions: Bupivacaine 0.25%, Dexamethasone, normal saline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus, Bone Remodeling
Interventions: exenatide, Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Major Depressive Disorder
Interventions: GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more

Conditions: Endometriosis
Interventions: Bupivacaine Hydrochloride, Normal saline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tibial Meniscus Injuries, Knee Injuries, Knee Injuries and Disorders
Interventions: Lipogems, Normal Saline; Device · Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions: normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U; Drug · Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Obesity, Menopausal Syndrome
Interventions: Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 62 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Infiltration of Peripheral IV Therapy
Interventions: ivWatch Model 400 with Milky Way Sensor; Device
Lead sponsor: ivWatch, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Newport News, Virginia

Search by objective public record fields.

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant

Stroke Volume-based Fluid Resuscitation in AP

Double Blinded Randomized Control Trial of Types of IVF in Children With DKA

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Inositol to Reduce Retinopathy of Prematurity

Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection

Central Sodium Sensing: Implications for Blood Pressure Regulation

Transversus Abdominis Plane (TAP) Block After Kidney Transplantation

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis

Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Regulation of Cortisol Metabolism and Fat Patterning

IVIG for Infection Prevention After CAR-T-Cell Therapy

Milky Way Sensor: Device Validation for Infiltrated Tissues